Dr. John-Michael Sauer, a 15-year veteran of pharmaceutical research and development, will lead the Predictive Safety Testing Consortium
TUCSON, Ariz. (June 10, 2013)—Critical Path Institute’s (C-Path) leaders announced today that John-Michael Sauer, PhD, has joined the organization as Executive Director of the Predictive Safety Testing Consortium (PSTC), C-Path’s longest standing consortium. Dr. Sauer, who received his doctorate in pharmacology and toxicology from the University of Arizona, most recently led research teams at Pfizer-CovX in San Diego, Calif., and Covance in Chandler, Ariz.
PSTC brings together pharmaceutical companies to share and validate each other’s safety testing methods under the advisement of the Food and Drug Administration (FDA), its European counterpart, the European Medicines Agency (EMA) and its counterpart in Japan, the Japanese Pharmaceutical and Medical Devices Agency (PMDA).
“We are very excited to have John-Michael join our team and lead this extremely important consortium,” said C-Path President and CEO, Martha Brumfield. “PSTC fills a critical global role by serving as a neutral third party in assessing drug safety tests, and John-Michael’s impressive background and experience will greatly add to the consortium’s collaborative efforts among industry and regulatory scientists.”
Prior to his work at Pfizer-CovX and Covance, Dr. Sauer held several senior positions at Elan Corporation and Eli Lilly and Company. Dr. Sauer also served as the project leader for the National Toxicology Program (NTP) within the Center for Toxicology at the University of Arizona.
PSTC is one of seven consortia under the C-Path umbrella working on a variety of research tools for a diverse set of organ toxicity programs including kidney, liver, skeletal muscle and others.
About Critical Path Institute
Established in 2005 as a non-profit organization, C-Path was formed with public and private philanthropic support from the University of Arizona, the US Food and Drug Administration (FDA), and the Tucson community. Additional funding has been provided by Science Foundation Arizona (SFAz). C-Path is committed to improving human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. An international leader in forming collaborations around this mission, C-Path has established global, public-private partnerships that include more than 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations, and 41 major pharmaceutical companies. C-Path is headquartered in Tucson, AZ.
Allison Schott 520-647-8380 email@example.com